
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7289411/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
2	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
3	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
4	Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2012, 36, 173-184.	3.7	468
5	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, e180071.	7.1	404
6	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncology, 2019, 5, e185896.	7.1	347
7	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics, 2013, 45, 253-261.	21.4	324
8	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
9	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	1.6	254
10	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research, 2010, 70, 5901-5911.	0.9	245
11	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	9.4	245
12	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 1313-1320.	7.0	240
13	Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas. American Journal of Surgical Pathology, 2014, 38, 437-447.	3.7	216
14	Schwann cells induce cancer cell dispersion and invasion. Journal of Clinical Investigation, 2016, 126, 1538-1554.	8.2	176
15	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer, 2014, 120, 2316-2324.	4.1	170
16	Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. American Journal of Surgical Pathology, 2009, 33, 1639-1645.	3.7	155
17	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer, 2015, 121, 1195-1203.	4.1	146
18	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	5.5	144

#	Article	IF	CITATIONS
19	KRAS and BRAF: drug targets and predictive biomarkers. Journal of Pathology, 2011, 223, 220-230.	4.5	133
20	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	1.6	129
21	<i>KRAS</i> mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer, 2014, 120, 3965-3971.	4.1	127
22	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
23	GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2008-17.	7.1	102
24	Genetic and phenotypic analysis of B ell postâ€ŧransplant lymphoproliferative disorders provides insights into disease biology. Hematological Oncology, 2008, 26, 199-211.	1.7	89
25	Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. Modern Pathology, 2010, 23, 12-26.	5.5	89
26	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. American Journal of Surgical Pathology, 2011, 35, 447-454.	3.7	82
27	Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Modern Pathology, 2013, 26, 131-138.	5.5	82
28	Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget, 2017, 8, 66117-66127.	1.8	80
29	Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival. Journal of Gastrointestinal Surgery, 2008, 12, 91-100.	1.7	77
30	A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions. American Journal of Surgical Pathology, 2017, 41, 980-988.	3.7	77
31	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	5.5	74
32	Inflammatory Monocytes Promote Perineural Invasion via CCL2-Mediated Recruitment and Cathepsin B Expression. Cancer Research, 2017, 77, 6400-6414.	0.9	73
33	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	7.3	73
34	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
35	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 101-111.	2.3	67
36	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	7.1	66

#	Article	IF	CITATIONS
37	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
38	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	7.0	62
39	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. American Journal of Surgical Pathology, 2018, 42, 705-714.	3.7	61
40	A phase 2 study of the insulinâ€like growth factorâ€1 receptor inhibitor MKâ€0646 in patients with metastatic, wellâ€differentiated neuroendocrine tumors. Cancer, 2012, 118, 4795-4800.	4.1	59
41	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
42	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery, 2013, 3, 294-307.	9.4	53
43	Successful Bilateral Lung Transplantation for Pulmonary Fibrosis Associated With the Hermansky-Pudlak Syndrome. Journal of Heart and Lung Transplantation, 2005, 24, 1697-1699.	0.6	52
44	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathology, 2015, 28, 1123-1129.	5.5	51
45	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2200-2208.	7.0	51
46	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
47	Radiation Impairs Perineural Invasion by Modulating the Nerve Microenvironment. PLoS ONE, 2012, 7, e39925.	2.5	48
48	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
49	Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns. American Journal of Surgical Pathology, 2018, 42, 1334-1345.	3.7	45
50	Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer, 2017, 123, 1134-1143.	4.1	43
51	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Human Pathology, 2014, 45, 2430-2436.	2.0	41
52	Pathologic Features and Biologic Importance of Colorectal Serrated Polyps. Advances in Anatomic Pathology, 2009, 16, 79-91.	4.3	40
53	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer, 2017, 123, 568-575.	4.1	39
54	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	2.5	38

#	Article	IF	CITATIONS
55	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 207-212.	2.3	37
56	Hepatitis C–Associated Granulomas After Liver Transplantation. American Journal of Clinical Pathology, 2007, 127, 128-134.	0.7	35
57	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. Journal of Surgical Oncology, 2016, 114, 637-641.	1.7	35
58	Logarithmic expansion of LGR5 + cells in human colorectal cancer. Cellular Signalling, 2018, 42, 97-105.	3.6	35
59	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	1.6	34
60	Immediate Postablation ¹⁸ F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases. Journal of Nuclear Medicine, 2018, 59, 1360-1365.	5.0	33
61	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology, 2019, 32, 110-121.	5.5	28
62	Acinar Cell Carcinoma of the Pancreas Metastatic to the Ovary. American Journal of Surgical Pathology, 2008, 32, 1540-1545.	3.7	27
63	Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. Familial Cancer, 2015, 14, 61-68.	1.9	27
64	Recurrent, truncating <i>SOX9</i> mutations are associated with SOX9 overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
65	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clinical Cancer Research, 2021, 27, 4101-4108.	7.0	24
66	HER2 Testing in Gastric and Gastroesophageal Adenocarcinomas. Advances in Anatomic Pathology, 2015, 22, 194-201.	4.3	23
67	Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. Journal of Gastrointestinal Oncology, 2015, 6, 668-75.	1.4	22
68	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. Molecular Cancer Research, 2015, 13, 1003-1008.	3.4	20
69	Cdc42 Mediates Cancer Cell Chemotaxis in Perineural Invasion. Molecular Cancer Research, 2020, 18, 913-925.	3.4	19
70	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Human Pathology, 2016, 53, 97-104.	2.0	18
71	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Familial Cancer, 2017, 16, 525-529.	1.9	18
72	Fluorescent Tissue Assessment of Colorectal Cancer Liver Metastases Ablation Zone: A Potential Real-Time Biomarker of Complete Tumor Ablation. Annals of Surgical Oncology, 2019, 26, 1833-1840.	1.5	18

#	Article	IF	CITATIONS
73	The Spectrum of B-Cell Non-Hodgkin Lymphomas With Dual <i>IgH</i> - <i>BCL2</i> and <i>BCL6</i> Translocations. American Journal of Clinical Pathology, 2008, 130, 193-201.	0.7	17
74	Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 438-443.	1.2	17
75	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology, 2017, 62, 74-82.	2.0	17
76	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. Familial Cancer, 2018, 17, 225-228.	1.9	17
77	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. Oncolmmunology, 2018, 7, e1435227.	4.6	16
78	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. JNCI Cancer Spectrum, 2019, 3, pkz015.	2.9	16
79	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	5.9	16
80	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. Human Pathology, 2019, 83, 1-6.	2.0	14
81	Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases. Cancers, 2022, 14, 693.	3.7	14
82	CD117 expression in diffuse large B-cell lymphomas: Fact or fiction?. Pathology International, 2005, 55, 716-723.	1.3	13
83	Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?. Modern Pathology, 2022, 35, 1515-1528.	5.5	13
84	Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. Human Pathology, 2019, 91, 19-25.	2.0	12
85	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Modern Pathology, 2019, 32, 1551-1562.	5.5	12
86	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist, 2022, 27, 380-388.	3.7	12
87	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	1.8	10
88	Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1098-1104.	2.5	9
89	Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care. Clinical Cancer Research, 2021, 27, 5891-5899.	7.0	9
90	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer, 2020, 20, 201-213.	1.9	8

#	Article	IF	CITATIONS
91	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 817-825.	1.5	8
92	T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: A case report and review of the literature. American Journal of Hematology, 2005, 80, 216-222.	4.1	6
93	Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?. Journal of Vascular and Interventional Radiology, 2022, 33, 308-315.e1.	0.5	6
94	SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate Journal of Clinical Oncology, 2017, 35, 587-587.	1.6	5
95	Molecular Testing of Colorectal Cancer in the Modern Era. Surgical Pathology Clinics, 2017, 10, 1009-1020.	1.7	4
96	Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 3519-3519.	1.6	4
97	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival. Annals of Surgery, 2022, 275, 371-381.	4.2	4
98	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. Oncolmmunology, 2020, 9, 1841948.	4.6	3
99	Total neoadjuvant therapy for locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 662-662.	1.6	3
100	Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC) Journal of Clinical Oncology, 2018, 36, 3520-3520.	1.6	3
101	Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography. Diagnostics, 2022, 12, 984.	2.6	2
102	Evolution in multimodality management of locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 684-684.	1.6	1
103	Poorly differentiated clusters as a prognostic marker at the invasive front of colon cancer Journal of Clinical Oncology, 2017, 35, 621-621.	1.6	1
104	Variability in genomic alterations between right- and left-sided microsatellite stable (MSS) metastatic colorectal cancer and impact on survival Journal of Clinical Oncology, 2017, 35, 3534-3534.	1.6	1
105	Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer Journal of Clinical Oncology, 2019, 37, 3585-3585.	1.6	1
106	Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. JCO Precision Oncology, 2022, , .	3.0	1
107	The 2011 Fred Waldorf Stewart Award Recipient. American Journal of Surgical Pathology, 2012, 36, 479-480.	3.7	0
108	Gene Expression Analysis of B-Cell Post Transplant Lymphoproliferative Disorders Provides Insights into Disease Biology Blood, 2007, 110, 3172-3172.	1.4	0

#	Article	IF	CITATIONS
109	Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients Journal of Clinical Oncology, 2017, 35, 3581-3581.	1.6	0
110	Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes Journal of Clinical Oncology, 2020, 38, 4602-4602.	1.6	0